Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2005 2
2007 3
2009 1
2010 1
2012 2
2014 2
2015 7
2016 5
2017 5
2018 12
2019 8
2020 12
2021 10
2022 7
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Among authors: downey dg. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
Rebuttal From Dr Downey.
Downey DG. Downey DG. Chest. 2022 Jan;161(1):24. doi: 10.1016/j.chest.2021.06.019. Chest. 2022. PMID: 35000703 No abstract available.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Among authors: downey dg. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Theratyping in cystic fibrosis.
Crawford KJ, Downey DG. Crawford KJ, et al. Among authors: downey dg. Curr Opin Pulm Med. 2018 Nov;24(6):612-617. doi: 10.1097/MCP.0000000000000521. Curr Opin Pulm Med. 2018. PMID: 30124524 Review.
Neutrophils in cystic fibrosis.
Downey DG, Bell SC, Elborn JS. Downey DG, et al. Thorax. 2009 Jan;64(1):81-8. doi: 10.1136/thx.2007.082388. Thorax. 2009. PMID: 19103874 Review.
Airway Inflammation and Host Responses in the Era of CFTR Modulators.
Keown K, Brown R, Doherty DF, Houston C, McKelvey MC, Creane S, Linden D, McAuley DF, Kidney JC, Weldon S, Downey DG, Taggart CC. Keown K, et al. Among authors: downey dg. Int J Mol Sci. 2020 Sep 2;21(17):6379. doi: 10.3390/ijms21176379. Int J Mol Sci. 2020. PMID: 32887484 Free PMC article. Review.
74 results